| SAN DIEGO, May 2, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV) announced today that the Company has initiated development of a diagnostic test to determine the presence of high risk Human Papilloma Virus (HPV) subtypes from urine specimens. The proprietary test (U.S. patent application pending) might, once available, be particularly useful for the determination of carrier status in males. The Company's HPV detection assay is a unique, proprietary(1) method that preferentially amplif...continued TROV |
Wednesday, May 2, 2012
Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment